RecruitingNot ApplicableNCT07722884

Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Safety and Efficacy of Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Sponsor

Ain Shams University

Enrollment

90 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Efficacy Safety Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms Monotherapy Tamsulosin Tadalafil

Summary

This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs. 5 mg) on lower urinary tract symptoms (LUTS) severity and patient quality of life in men with benign prostatic hyperplasia (BPH). It also seeks to determine whether the lower tadalafil dose provides adequate symptom relief while minimizing adverse effects over a 12-week follow-up period.

Eligibility

Min Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tamsulosin 0.4 mg, a drug called Tamsulosin 0.4 mg + Tadalafil 2.5 mg, and others for people with benign prostatic hyperplasia, efficacy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.